Rofucal (Hydrochlorothiazide) is relevant for easing symptoms related to fluid volume excess and managing systemic pressure imbalances. It is commonly used to address high blood pressure and fluid retention.

Therapeutic Scope and Benefits

This medication is generally applied across conditions presenting with systemic discomfort, and its core benefit helps patients cope during periods when symptoms become more noticeable. Rofucal is commonly used for managing essential hypertension and edematous states, including those linked to chronic conditions like congestive heart failure, hepatic cirrhosis, and various forms of renal dysfunction. Furthermore, it is considered relevant for specialized support appropriate for individuals with recurrent calcium kidney stone formation and nephrogenic diabetes insipidus.

“It assists with maintaining functional stability during periods when blood pressure readings may be more noticeable, contributing to the easing of the overall symptom load.”

By providing supportive relief from peripheral swelling in the lower extremities, Rofucal helps maintain a sense of stability, and may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Relief for Peripheral Swelling Rofucal plays a role in managing fluid volume, which provides supportive relief from the symptom clusters of swelling and discomfort, particularly in the ankles and feet.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Rofucal?

The eligibility for Rofucal (Hydrochlorothiazide) is strictly defined by regulatory documents, distinguishing between approved populations, restricted use, and absolute contraindications.

Contraindicated Populations (Must Not Use)

Use of Rofucal is contraindicated in patients with:

• Anuria (inability to urinate).
• Known hypersensitivity to Hydrochlorothiazide or any sulfonamide-derived drugs.
• Severe renal impairment or severe hepatic impairment.
• Refractory hypokalaemia or hypercalcaemia.
• The second and third trimesters of pregnancy.

---

Age and Life Stage Eligibility

Population	Regulatory Status
Adults	Approved population for treatment.
Pediatric Patients	Approved for use, though general regulatory statements indicate safety and effectiveness are not established in all pediatric groups.
Geriatric Patients	May require dose adjustment due to age-related organ changes, and use should begin with the lowest available dose.

---

Restricted or Conditional Use

The medicine must be used with caution in patients with conditions such as Systemic Lupus Erythematosus (SLE), impaired hepatic function (due to the risk of hepatic coma), impaired renal function, or a history of gout/hyperuricemia. For nursing mothers, a decision is required to either discontinue nursing or discontinue the drug, as thiazides are excreted in breast milk.

Interactions with other medicines and products

The interaction profile of Rofucal, which contains Hydrochlorothiazide (HCTZ), is defined by its effects on renal clearance, gastrointestinal absorption, and pharmacodynamic potentiation, as documented in official government regulatory sources.

Documented Interaction Patterns

Interaction Type	Interacting Substances	Regulatory Statement
Reduced Clearance	Lithium	HCTZ reduces the renal clearance of lithium, leading to a high risk of lithium toxicity; co-administration is generally not recommended.
Reduced Absorption	Cholestyramine, Colestipol Resins	These agents bind HCTZ, significantly reducing its absorption.
Pharmacodynamic Potentiation	Other Antihypertensives	Results in an additive blood pressure-lowering effect.
Electrolyte Intensification	Corticosteroids, ACTH	Leads to intensified electrolyte depletion, particularly the risk of hypokalemia.
Effect Antagonism	NSAIDs	Can reduce the diuretic and antihypertensive effects of HCTZ.

Administration Constraints

The interaction with Cholestyramine and Colestipol requires strict time separation: Rofucal must be administered at least 1 hour before or 4 to 6 hours after the administration of the binding resin. Furthermore, the combination with Aliskiren is officially contraindicated in patients with diabetes due to increased risks of severe adverse outcomes. The concurrent use of alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension.

Modulation of Renal Ion Transport

Rofucal exerts its primary effect by modulating renal ion transport, initiating a sequence that alters fluid and electrolyte dynamics. The drug acts by inhibiting the sodium-chloride symporter (NCC) located in the apical membrane of epithelial cells in the distal convoluted tubules of the kidneys. This molecular interaction is a key step that reduces the reabsorption of both sodium (Na^+) and chloride (Cl^-) ions from the tubular fluid.

---

Downstream Physiological Consequence

The suppression of NCC activity initiates a mechanistic cascade resulting in increased delivery of sodium and water to the collecting ducts. This modifies subsequent molecular steps that ultimately increase the urinary excretion of water, sodium, potassium, and chloride. Beyond the direct renal effect, Rofucal engages mechanisms that lead to a reduction in peripheral vascular resistance, contributing to system-level physiological modulation that adjusts vascular tone and fluid dynamics.

Administration and Dosing Principles

Rofucal, which contains hydrochlorothiazide, is administered orally and is available as tablets, capsules, and a powder for oral suspension. When the suspension form is utilized, the protocol involves reconstitution with water and measurement using a calibrated dosing tool to ensure administration accuracy.

Dosing Schedule and Timing

The schedule is typically once daily, although higher regimens, particularly for edema, may involve two divided doses or an intermittent schedule. To mitigate sleep disruption from nocturia, Rofucal is generally taken in the morning, and it can be administered with or without food.

Standard adult dosing for essential hypertension typically starts at 12.5 mg to 25 mg once daily and should not exceed a maintenance dose of 50 mg per day. For managing edematous states, the dose is generally higher, ranging from 25 mg to 100 mg daily.

Population-Specific Instructions

For older adults, therapy is initiated at the lowest available strength. Furthermore, Rofucal is not recommended in cases of severe renal impairment (CrCl <30 mL/min), as its effectiveness is diminished. If a dose is missed, it is generally advised to take it when remembered unless it is near the next scheduled time, with the emphasis that double doses should be strictly avoided. These procedural and dosage parameters define the standard use protocol for the medication.

Research Evidence / Overview of Studies for Rofucal (Hydrochlorothiazide)

This overview summarizes the key clinical evidence used to evaluate Rofucal's active ingredient, Hydrochlorothiazide, focusing on the types of studies conducted, the populations examined, and the consistency of the findings reported in governmental and peer-reviewed scientific literature.

---

Evidence for Use in Managing Essential Hypertension

The research evidence for the active ingredient was studied for use in hypertension and includes extensive Randomized Controlled Trials (RCTs) and large-scale Systematic Reviews and Meta-Analyses. Studies examined how treatment was associated with changes in systolic and diastolic blood pressure (BP) readings and monitored long-term outcomes reflecting daily functioning, such as tracking the occurrence of major cardiovascular events. Findings from the diuretic drug class generally describe patterns related to blood pressure readings. Evidence quality varies across studies when comparing Rofucal’s active ingredient to certain other diuretics for cardiovascular event outcomes, meaning that comparative evidence is lacking in some large-scale trials.

---

Evidence for Use in Managing Edematous States (Fluid Retention)

Rofucal's active ingredient was studied for its role in fluid retention based on supporting observational data. Research explored its potential influence on outcomes related to systemic or functional imbalance by tracking physical swelling, particularly when used in patients with underlying chronic conditions like Congestive Heart Failure or Hepatic Cirrhosis. It is not yet clear whether the long-term outcomes of using the active ingredient alone can be reliably predicted from the current data, as much of the recent data is derived from settings with varying symptom burdens where the medicine was used in combination with other therapies.

---

Evidence in Specific Patient Populations

The extensive high blood pressure research was evaluated in a significant number of older adults (≥ 65 years). The research also examined patients with co-existing health conditions like diabetes or a history of stroke. However, data for certain groups remain insufficient. For instance, most studies focused on adults, and limited information for long-term outcomes is available for use in children. Because results apply only to the populations studied, the applicability of these findings to individuals with complex underlying health issues not specifically studied remains uncertain.

Key Studies & References

1. Hydrochlorothiazide: StatPearls - NCBI
2. NICE Guideline: Chronic heart failure in adults: diagnosis and management (2018, updated 2023)

Common questions about Rofucal (FAQ)

---

Q: What specific condition or symptoms is Rofucal approved to treat?

Official regulatory documents state that Rofucal is approved for the management of high blood pressure (hypertension). It is also indicated to treat fluid retention (edema) that may be caused by certain heart, liver, or kidney disorders.

Q: How will I know for sure if Rofucal is having the desired effect?

Regulatory guidance suggests effectiveness is determined through clinical assessment. Effectiveness is generally evaluated by healthcare providers through monitoring blood pressure and observing changes in fluid retention over a course of treatment.

Q: Are there any common side effects of Rofucal that typically go away after the first week?

The official product information notes that some effects, such as dizziness or lightheadedness upon standing (orthostatic hypotension), may be more noticeable when treatment is starting. The regulatory label specifies certain effects, but it does not provide explicit timeframes for when all common side effects might be expected to fully resolve.

Q: What are the signs of a severe or concerning side effect from Rofucal?

Severe reactions are documented in official sources and represent situations where contacting a healthcare professional is appropriate. These signs can include sudden changes in vision or eye pain, symptoms of a severe allergic reaction like difficulty breathing or rash, or signs of a serious electrolyte imbalance.

Q: Does Rofucal commonly cause drowsiness or affect a person's ability to drive?

The medicine itself is not expected to directly impact alertness. However, documented side effects like dizziness or faintness may occasionally occur. Because these effects may cause potential impairment, official information recommends awareness of this before driving or operating machinery.

Q: Does taking Rofucal affect the results of routine blood tests?

Yes, Rofucal can affect the results of certain laboratory tests. These changes are typically seen in serum electrolyte levels, glucose, and calcium. Official labeling notes that the drug may require temporary discontinuation prior to certain tests, such as those for parathyroid function.

Q: What kind of monitoring is generally suggested for patients on Rofucal?

Regulatory documents emphasize the importance of regular monitoring. Healthcare providers typically suggest periodically checking your serum electrolyte levels to detect potential imbalances. Regular blood pressure readings are also necessary to track the drug's intended function.

Q: Does Rofucal cause changes in mood or sleep patterns?

Official documentation lists nervous system effects such as restlessness and anxiety as potential adverse reactions. These symptoms can sometimes be related to shifts in the body's fluid and electrolyte balance. Drowsiness has also been documented as a possible warning sign.

Q: How quickly should a patient expect Rofucal to start working?

The diuretic effect, which increases urination, is generally observed within approximately two hours of taking the dose. For its main purpose of lowering blood pressure, the full effect may take longer to develop, typically reaching its maximum reduction after about two to four weeks of consistent treatment.

Q: Is Rofucal intended to be a long-term or short-term treatment?

According to official information, Rofucal is typically utilized as a long-term treatment option for high blood pressure. Because the drug manages the condition rather than curing it, continuous administration is frequently utilized for sustained management.

Q: Does Rofucal interact with any common herbal supplements like St. John's Wort?

The regulatory label cautions against combining the drug with many substances due to the risk of altering the drug's effect or increasing side effects. Regulatory information advises that patients discuss all herbal products and nutritional supplements they are using with their healthcare provider.

Q: What happens if a patient stops taking Rofucal suddenly?

Official sources describe the potential for severe rebound in blood pressure or a rapid return of fluid retention if the drug is stopped suddenly. Patients should consult a healthcare provider regarding any change in therapy.

Q: Are there any foods or beverages that are specifically mentioned to avoid with Rofucal?

The drug's mechanism of action is often supported by a low-sodium diet, which may be discussed with a healthcare provider. Additionally, the regulatory information notes that alcohol intake may increase the risk of side effects like dizziness.

Q: Does Rofucal have a 'boxed warning' in the regulatory documentation?

The FDA label for Rofucal's active ingredient does not contain a Boxed Warning. However, the regulatory documentation does include serious safety information and warnings regarding the potential risk of non-melanoma skin cancer and possible fetal toxicity.

Q: Has Rofucal been studied in specific ethnic groups or populations?

Clinical trial data found in regulatory documentation sometimes notes observations regarding the drug's effects across different ethnic or racial backgrounds. This data contributes to the comprehensive understanding of the drug’s response profile.

Q: Is it possible to develop a dependency on Rofucal?

Official regulatory bodies do not classify the drug as a controlled substance. This classification indicates that the drug has a low potential for abuse or dependency.

Q: Is Rofucal known to cause weight gain or weight loss?

The drug's primary action is as a diuretic, which promotes the excretion of excess water and sodium from the body. This mechanism typically results in initial body weight loss due to the reduction of retained fluid.

Q: Is Rofucal intended to be a cure, or a treatment for symptoms?

The official regulatory indication is for the management of high blood pressure and fluid retention. This means Rofucal is used to control the symptoms and support the condition rather than providing a permanent cure.

Q: Are there known interactions between Rofucal and commonly prescribed antidepressants?

Yes, regulatory information states that concurrent use with certain antidepressant medications may increase the risk of a condition called hyponatremia (low sodium levels in the blood). The need for monitoring sodium levels is generally evaluated when these medications are utilized together.

Q: Is Rofucal a controlled substance or a restricted drug?

The drug is not listed as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.

Q: What are the official patient information resources for Rofucal?

Official, reliable patient information is published by government health authorities. These resources include databases like FDA DailyMed and the NIH's MedlinePlus, which provide the drug’s regulatory label and patient-friendly summaries.

How to Store and Dispose of Rofucal (Hydrochlorothiazide)

The storage and disposal requirements for Rofucal (Hydrochlorothiazide) are set by official regulatory labeling to maintain the drug's stability and ensure safety.

Official Storage Conditions

Rofucal must be stored at Controlled Room Temperature, which is officially defined as 68 F to 77 F (20 C to 25 C). The medication must be kept in its original container and the container must remain tightly closed to protect the drug from moisture.

Child Safety and Disposal

For safety, the product must always be stored out of the sight and reach of children.

Unused or expired Rofucal must be disposed of according to local regulatory requirements. Unless specifically instructed otherwise by a health authority, the medication should not be flushed down a toilet or poured into a drain.